We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-1.84%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.85B
AUM Growth
+$135M
Cap. Flow
-$725M
Cap. Flow %
-39.12%
Top 10 Hldgs %
58.55%
Holding
374
New
79
Increased
68
Reduced
92
Closed
116

Top Buys

Rank Stock Value
1
BIOA
BioAmber Inc.
BIOA
+$5.55M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$5.2M
3
OTIC
Otonomy, Inc.
OTIC
+$3.92M
4
BLRX
BioLineRX
BLRX
+$3.37M
5
SLS icon
SELLAS Life Sciences
SLS
+$2.7M

Top Sells

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$62.4M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$59.7M
3
AMGN icon
Amgen
AMGN
+$35.8M
4
LLY icon
Eli Lilly
LLY
+$15.7M
5
BIIB icon
Biogen
BIIB
+$5.67M

Sector Composition

Rank Sector Weight
1 Healthcare 6.29%
2 Materials 0.25%
3 Financials 0.16%
4 Consumer Staples 0.04%
5 Consumer Discretionary 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CYTK icon
76
CALL
Cytokinetics
CYTK
$10.6B
$2.6M 0.14%
+2,023
New +$23.6K
STML
77
DELISTED
Stemline Therapeutics, Inc.
STML
$2.48M 0.13%
290,087
-67,719
-19% -$617K
UTHR icon
78
United Therapeutics
UTHR
$26.1B
$2.35M 0.13%
+17,342
New +$2.63M
PBYI icon
79
PUT
Puma Biotechnology
PBYI
$398M
$2.33M 0.13%
626
-1,073
-63% -$39.2K
KYNB
80
CALL
Kyntra Bio
KYNB
$27.4M
$2.32M 0.13%
38
-10
-21% -$6.09K
KITE
81
PUT
DELISTED
Kite Pharma, Inc.
KITE
$2.28M 0.12%
291
– –
AVXS
82
CALL
DELISTED
AveXis, Inc. Common Stock
AVXS
$2.28M 0.12%
+300
New +$18.6K
LXRX icon
83
CALL
Lexicon Pharmaceuticals
LXRX
$1.03B
$2.24M 0.12%
1,563
– –
ARRY
84
PUT
DELISTED
Array Biopharma Inc
ARRY
$2.23M 0.12%
+2,500
New +$26.6K
PRTK
85
CALL
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$2.2M 0.12%
+1,141
New +$18K
SCPX
86
DELISTED
Scorpius Holdings, Inc.
SCPX
$2.18M 0.12%
+9
New +$2.31M
ABUS icon
87
Arbutus Biopharma
ABUS
$847M
$2.11M 0.11%
648,200
-144,417
-18% -$401K
SPNC
88
DELISTED
Spectranetics Corp
SPNC
$2.1M 0.11%
+72,000
New +$1.92M
SAGE
89
CALL
DELISTED
Sage Therapeutics
SAGE
$2.05M 0.11%
288
-561
-66% -$32.9K
PSTV icon
90
Plus Therapeutics
PSTV
$25M
$2.03M 0.11%
7
-2
-22% -$617K
EDIT icon
91
Editas Medicine
EDIT
$399M
$2.02M 0.11%
90,300
-24,700
-21% -$512K
BPMC
92
DELISTED
Blueprint Medicines
BPMC
$2M 0.11%
+50,000
New +$1.79M
CHRS icon
93
Coherus Oncology
CHRS
$217M
$1.97M 0.11%
93,308
+64,690
+226% +$1.59M
NTLA icon
94
Intellia Therapeutics
NTLA
$1.51B
$1.97M 0.11%
140,000
+10,000
+8% +$134K
PRTK
95
PUT
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$1.97M 0.11%
+1,025
New +$16.1K
OCGN icon
96
Ocugen
OCGN
$403M
$1.9M 0.1%
18,257
+2,509
+16% +$253K
STML
97
CALL
DELISTED
Stemline Therapeutics, Inc.
STML
$1.86M 0.1%
2,174
+1,818
+511% +$16.6K
SGMO
98
CALL
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$1.82M 0.1%
3,493
-2,684
-43% -$10.8K
FLXN
99
PUT
DELISTED
Flexion Therapeutics, Inc.
FLXN
$1.77M 0.1%
659
+411
+166% +$8.39K
RDUS
100
PUT
DELISTED
Radius Health, Inc.
RDUS
$1.75M 0.09%
454
-736
-62% -$30.9K
2 3
4
5 6

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
AB
Aozora Bank Tokyo, Japan $43.6M AUM 1.15% 1-Year Est. Return

Sabby Management's Q1 2017 Portfolio in Review

As of Q1 2017, Sabby Management held 374 positions worth $1.85B, up 7.8% from $1.72B the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Sabby Management withdrew a net $725M in Q1 2017, closing 116 positions and reducing 92 holdings. Its most notable exit was Sarepta Therapeutics, an estimated $62.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 6.3% of assets, down from 18% a quarter earlier, followed by Materials and Financials.

Against the trend, Sabby Management opened a new position in BioAmber Inc. worth $3.39M.

  • Sabby Management's largest Q1 2017 buy was BioAmber Inc.: 1,460,859 shares worth $3.39M.
  • Sabby Management added most to Otonomy, Inc. in Q1 2017, an estimated $3.92M increase.
  • Sabby Management's biggest Q1 2017 reduction was Amgen, cutting an estimated $35.8M.
  • Sabby Management fully exited Sarepta Therapeutics in Q1 2017, selling an estimated $62.4M.
  • Sabby Management's ten largest holdings make up 59% of its $1.85B portfolio in Q1 2017.
  • Sabby Management opened 79 new positions and closed 116 in Q1 2017.
  • Sabby Management's portfolio value rose 7.8% quarter-over-quarter to $1.85B.

Based on Sabby Management's 13F filing for Q1 2017, filed 15 May 2017.